Disordered Signaling in Myeloproliferative Neoplasms

Hematology/Oncology Clinics of North America

Volumn 26, Issue 5, 2012, Pages 1017-1035

  Anand, Shubha ^a   Huntly, Brian J P ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Erythropoietin receptor; JAK2; MPL; Myeloproliferative neoplasms; Signaling

Indexed keywords

CBL PROTEIN; COLONY STIMULATING FACTOR 1; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE 2; PHENYLALANINE; PROTEIN; PROTEIN LNK; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; VALINE;

CHROMATIN; CODON; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; DOWNSTREAM PROCESSING; EXON; GENE MUTATION; HUMAN; IN VIVO STUDY; INFORMATION PROCESSING; MUTATION; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

HUMANS; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84866599188     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.07.004     Document Type: Review

References (109)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372-375.
2. Campbell P.J., Green A.R. The myeloproliferative disorders. N Engl J Med 2006, 355:2452-2466.
3. Levine R.L., Pardanani A., Tefferi A., et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673-683.
4. Prchal J.F., Axelrad A.A. Letter: bone-marrow responses in polycythemia vera. N Engl J Med 1974, 290:1382.
5. Casadevall N., Vainchenker W., Lacombe C., et al. Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood 1982, 59:447-451.
6. Cashman J., Henkelman D., Humphries K., et al. Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny. Blood 1983, 61:876-884.
7. Eaves C.J., Eaves A.C. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978, 52:1196-1210.
8. Fisher M.J., Prchal J.F., Prchal J.T., et al. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994, 84:1982-1991.
9. Zanjani E.D., Lutton J.D., Hoffman R., et al. Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest 1977, 59:841-848.
10. Correa P.N., Eskinazi D., Axelrad A.A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994, 83:99-112.
11. Dai C.H., Krantz S.B., Dessypris E.N., et al. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992, 80:891-899.
12. Dai C.H., Krantz S.B., Green W.F., et al. Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994, 86:12-21.
13. Dai C.H., Krantz S.B., Means R.T., et al. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest 1991, 87:391-396.
14. Emanuel P.D., Eaves C.J., Broudy V.C., et al. Familial and congenital polycythemia in three unrelated families. Blood 1992, 79:3019-3030.
15. Means R.T., Krantz S.B., Sawyer S.T., et al. Erythropoietin receptors in polycythemia vera. J Clin Invest 1989, 84:1340-1344.
16. Hess G., Rose P., Gamm H., et al. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 1994, 88:794-802.
17. Le Couedic J.P., Mitjavila M.T., Villeval J.L., et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 1996, 87:1502-1511.
18. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
19. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
20. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
21. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
22. Rane S.G., Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19:5662-5679.
23. Rane S.G., Reddy E.P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21:3334-3358.
24. Feener E.P., Rosario F., Dunn S.L., et al. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 2004, 24:4968-4978.
25. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277:47954-47963.
26. Ungureanu D., Wu J., Pekkala T., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011, 18:971-976.
27. Baker S.J., Rane S.G., Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 2007, 26:6724-6737.
28. Huang L.J., Constantinescu S.N., Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001, 8:1327-1338.
29. Royer Y., Staerk J., Costuleanu M., et al. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 2005, 280:27251-27261.
30. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
31. Ihle J.N. The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Semin Immunol 1995, 7:247-254.
32. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792.
33. Lu X., Huang L.J., Lodish H.F. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008, 283:5258-5266.
34. Lu X., Levine R., Tong W., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005, 102:18962-18967.
35. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
36. Scott L.M. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011, 86:668-676.
37. Villeval J.L., Cohen-Solal K., Tulliez M., et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997, 90:4369-4383.
38. Yan X.Q., Lacey D., Fletcher F., et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995, 86:4025-4033.
39. Yan X.Q., Lacey D., Hill D., et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996, 88:402-409.
40. Yanagida M., Ide Y., Imai A., et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997, 99:739-745.
41. Pietra D., Brisci A., Rumi E., et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011, 96:607-611.
42. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.
43. Staerk J., Lacout C., Sato T., et al. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 2006, 107:1864-1871.
44. Marty C., Chaligne R., Lacout C., et al. Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. J Biol Chem 2009, 284:11781-11791.
45. Beer P.A., Campbell P.J., Scott L.M., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112:141-149.
46. Boyd E.M., Bench A.J., Goday-Fernandez A., et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010, 149:250-257.
47. Chaligne R., Tonetti C., Besancenot R., et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008, 22:1557-1566.
48. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
49. Tong W., Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004, 200:569-580.
50. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005, 105:4604-4612.
51. Velazquez L., Cheng A.M., Fleming H.E., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002, 195:1599-1611.
52. Bersenev A., Wu C., Balcerek J., et al. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008, 118:2832-2844.
53. Gery S., Gueller S., Chumakova K., et al. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007, 110:3360-3364.
54. Baran-Marszak F., Magdoud H., Desterke C., et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 2010, 116:5961-5971.
55. Gery S., Cao Q., Gueller S., et al. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009, 85:957-965.
56. Oh S.T., Simonds E.F., Jones C., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
57. Lasho T.L., Pardanani A., Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010, 363:1189-1190.
58. Pardanani A., Lasho T., Finke C., et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718.
59. Ha J.S., Jeon D.S. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol 2011, 86:866-868.
60. Hurtado C., Erquiaga I., Aranaz P., et al. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation. Leuk Res 2011, 35:1537-1539.
61. Lasho T.L., Tefferi A., Finke C., et al. Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia 2011, 25:1056-1058.
62. Bersenev A., Wu C., Balcerek J., et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010, 120:2058-2069.
63. Takaki S., Morita H., Tezuka Y., et al. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 2002, 195:151-160.
64. Kales S.C., Ryan P.E., Nau M.M., et al. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010, 70:4789-4794.
65. Joazeiro C.A., Wing S.S., Huang H., et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286:309-312.
66. Levkowitz G., Waterman H., Ettenberg S.A., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999, 4:1029-1040.
67. Yokouchi M., Kondo T., Houghton A., et al. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 1999, 274:31707-31712.
68. Saur S.J., Sangkhae V., Geddis A.E., et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010, 115:1254-1263.
69. Grand F.H., Hidalgo-Curtis C.E., Ernst T., et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009, 113:6182-6192.
70. Aranaz P., Hurtado C., Erquiaga I., et al. CBL mutations in myeloproliferative neoplasms are also found in its proline-rich domain and in patients with the V617FJAK2. Haematologica 2012, 97(8):1234-1241.
71. Dimitriou I.D., Clemenza L., Scotter A.J., et al. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol Rev 2008, 224:265-283.
72. Suessmuth Y., Elliott J., Percy M.J., et al. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol 2009, 147:450-458.
73. Jost E., do O.N., Dahl E., et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 2007, 21:505-510.
74. Teofili L., Martini M., Cenci T., et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008, 123:1586-1592.
75. Capello D., Deambrogi C., Rossi D., et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2008, 141:504-511.
76. Chaligne R., Tonetti C., Besancenot R., et al. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. Leukemia 2009, 23:1186-1190.
77. Elliott J., Suessmuth Y., Scott L.M., et al. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 2009, 94:576-580.
78. Hookham M.B., Elliott J., Suessmuth Y., et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007, 109:4924-4929.
79. Haan S., Wuller S., Kaczor J., et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 2009, 28:3069-3080.
80. Zou H., Yan D., Mohi G. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett 2011, 585:1007-1013.
81. Bumm T.G., Elsea C., Corbin A.S., et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006, 66:11156-11165.
82. Lacout C., Pisani D.F., Tulliez M., et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652-1660.
83. Wernig G., Mercher T., Okabe R., et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
84. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006, 1:e18.
85. Koppikar P., Abdel-Wahab O., Hedvat C., et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010, 115:2919-2927.
86. Akada H., Yan D., Zou H., et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
87. Li J., Spensberger D., Ahn J.S., et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116:1528-1538.
88. Marty C., Lacout C., Martin A., et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010, 116:783-787.
89. Mullally A., Lane S.W., Ball B., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
90. Li J., Kent D.G., Chen E., et al. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech 2011, 4:311-317.
91. Yan D., Hutchison R.E., Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012, 119(15):3539-3549.
92. Walz C., Ahmed W., Lazarides K., et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice. Blood 2012, 119(15):3550-3560.
93. Nelson E.A., Walker S.R., Weisberg E., et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011, 117:3421-3429.
94. Shah N.P., Shannon K. Advancing the STATus of MPN pathogenesis. Blood 2012, 119:3374-3376.
95. Mesa R.A., Tefferi A., Lasho T.S., et al. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia 2006, 20:1800-1808.
96. Schwemmers S., Will B., Waller C.F., et al. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol 2007, 35:1695-1703.
97. Teofili L., Martini M., Cenci T., et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 2007, 110:354-359.
98. Grimwade L.F., Happerfield L., Tristram C., et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009, 147:495-506.
99. Anand S., Stedham F., Gudgin E., et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 2011, 118:1610-1621.
100. Chen E., Beer P.A., Godfrey A.L., et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010, 18:524-535.
101. Shi S., Calhoun H.C., Xia F., et al. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet 2006, 38:1071-1076.
102. Dawson M.A., Bannister A.J., Gottgens B., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
103. Panteleeva I., Boutillier S., See V., et al. HP1alpha guides neuronal fate by timing E2F-targeted genes silencing during terminal differentiation. EMBO J 2007, 26:3616-3628.
104. Liu F., Zhao X., Perna F., et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011, 19:283-294.
105. Zhao Q., Rank G., Tan Y.T., et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009, 16:304-311.
106. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005, 23:8520-8530.
107. Fleischman A.G., Aichberger K.J., Luty S.B., et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011, 118:6392-6398.
108. Hoermann G., Cerny-Reiterer S., Herrmann H., et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J 2012, 26:894-906.
109. Manshouri T., Estrov Z., Quintas-Cardama A., et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011, 71:3831-3840.